Skip to main content
OpenTrials

Clinical trial condition

Refractory Diffuse Large B-Cell Lymphoma

Explore clinical trials studying Refractory Diffuse Large B-Cell Lymphoma. Study availability and eligibility vary by location and protocol.

66 public trials 20 recruiting studies
Refine in advanced search Browse all conditions

Refractory Diffuse Large B-Cell Lymphoma trial results

Completed

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

NCT04833114

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • UK Graz Universitätsklinik für Innere Medizin Klinische Abteilung für Hämatologie Graz, Austria
  • LKH Hochsteiermark Standort Leoben Abteilung für Innere Medizin Department für Hämato-Onkologie Leoben, Austria
  • Ordensklinikum Linz GmbH- Elisabethinen: I. Interne Abteilung Hämato-Onkologie Linz, Austria
  • Kepler Universitätsklinikum Med Campus III, Univ.-Klinik für Hämatologie und Internistische Onkologie Linz, Austria
View all 64 locations
View Trial Details
Completed

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

NCT05068440

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital Hefei, Anhui, China
  • Beijing Friendship Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Fujian Cancer Hospital Fuzhou, Fujian, China
  • Sun Yat Sen University Cancer Center Guangzhou, Guangdong, China
View all 25 locations
View Trial Details
Completed

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

NCT02568553

Conditions
Burkitt Lymphoma, Chronic Disease, DNA Virus Infections, +53 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
View all 24 locations
View Trial Details
Completed

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

NCT05075603

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +13 more
Locations
  • City of Hope Duarte, California, United States
  • Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center Detroit, Michigan, United States
  • Washington University in St. Louis St Louis, Missouri, United States
  • Duke Cancer Institute Durham, North Carolina, United States
View Trial Details
Completed

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

NCT05267054

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Beijing Friendship Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Beijing Hospital Beijing, Beijing Municipality, China
  • Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong, China
View all 19 locations
View Trial Details

Related conditions